… colitis, Transmembrane tumor necrosis factor, Apoptosis … inflammatory bowel diseases to
anti-tumor necrosis factor (TNF) therapy, it is mandatory to understand the pleiotropic effects of …

… Many of those actions are mediated by the binding of the antibodies to … molecular factors
and cells. In this review, we have highlighted new information on the mechanism of actions of …

… pro-inflammatory cytokines, chemokines, adhesion molecules, … Infliximab is a chimeric
antibody, in which a part of the Fab … Adalimumab and golimumab are fully human IgG1 antibodies. …

… anti–tumor necrosis factor α (TNF-α) therapies. The TNF-α cytokine is a major mediator in the
pathophysiology of inflammation … molecule has two antigen-binding sites, a single antibody …

… of being monoclonal antibodies are small molecules and thus relatively non-immunogenic. …
a small molecule fusion protein that is not immunogenic, unlike monoclonal antibodies. Early …

… mechanisms of action of antitumor necrosis factor α (anti-TNF-α) antibodies in the therapy
of inflammatory bowel … can react with three IFX molecules and one molecule of either IFX or …

… Tumor Necrosis Factor (TNF), a key, early signaling molecule in the inflammatory cascade.
… These antibodies are able to bind both soluble and membrane-bound TNF and block its …

… Biologics are generally large molecules (eg, monoclonal antibodies) that require parenteral
… -generation molecule that specifically interferes with leukocyte homing into the inflamed gut …

… with the anti–tumor necrosis factor (TNF) antibody infliximab … use of anti-TNF therapy for
inflammatory bowel disease. … is linked to the ability of the molecule to induce T-cell apoptosis. …

… However, the cellular and molecular mechanisms of actions of the anti-TNF antibodies …
anti–tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor …